Compiled 2026-09-26Data through 2025-04-252 min read
Dated source-based research · No live market data

Observation

Across 14 eligible healthcare companies, the equal-weight median equity as a share of assets was 39.38% for the prior selected annual periods.

Data context

The eligible sample covers 14 of 16 selected companies. The prior selected annual periods span 2024-12-31 to 2025-04-25. Companies have different fiscal year ends. This is a cross-sectional research sample, not a calendar-year index or a representation of the full sector.

Company evidence

LLY 18.13% (period 2024-12-31); ABBV 2.46% (period 2024-12-31); MRK 39.55% (period 2024-12-31); NVS 43.08% (period 2024-12-31); AZN 39.20% (period 2024-12-31); AMGN 6.40% (period 2024-12-31); GILD 32.77% (period 2024-12-31); ABT 58.55% (period 2024-12-31); PFE 41.33% (period 2024-12-31); ISRG 87.68% (period 2024-12-31); VRTX 72.82% (period 2024-12-31); BMY 17.64% (period 2024-12-31); MDT 52.38% (period 2025-04-25); HCA -4.20% (period 2024-12-31).

Distribution

The sample range is -4.20% (HCA) to 87.68% (ISRG). The median is computed across company ratios with equal weight; it is not a ratio of aggregate totals. Extreme values can reflect a small denominator or unusual accounting items.

Interpretation

Drug developers, device manufacturers and care providers depend on distinct clinical, reimbursement and operating economics. The numerator is shareholdersEquity; the denominator is total assets. Only positive denominators and disclosed numerators qualify. No missing value is replaced with zero.

What to watch

Product concentration, research investment, utilization, reimbursement and cash generation.

Research limitations

Patent expiry, trial outcomes, reimbursement changes, litigation and acquisition integration. The sample uses a September 18, 2026 source snapshot. It does not establish current market conditions, causal drivers or future returns. Sector labels are editorial and the financial-sector cash-flow measures need particular caution.

Company-level observations · percent
CompanyValuePeriod end
LLY18.13%2024-12-31
ABBV2.46%2024-12-31
MRK39.55%2024-12-31
NVS43.08%2024-12-31
AZN39.20%2024-12-31
AMGN6.40%2024-12-31
GILD32.77%2024-12-31
ABT58.55%2024-12-31
PFE41.33%2024-12-31
ISRG87.68%2024-12-31
VRTX72.82%2024-12-31
BMY17.64%2024-12-31
MDT52.38%2025-04-25
HCA-4.20%2024-12-31

Sources & dates